141 related articles for article (PubMed ID: 32762584)
1. Factor Xa and thrombin induce endothelial progenitor cell activation. The effect of direct oral anticoagulants.
Papadaki S; Sidiropoulou S; Moschonas IC; Tselepis AD
Platelets; 2021 Aug; 32(6):807-814. PubMed ID: 32762584
[TBL] [Abstract][Full Text] [Related]
2. Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?
Papadaki S; Tselepis AD
Angiology; 2019 Nov; 70(10):896-907. PubMed ID: 31010298
[TBL] [Abstract][Full Text] [Related]
3. Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatran.
Ellinghaus P; Perzborn E; Hauenschild P; Gerdes C; Heitmeier S; Visser M; Summer H; Laux V
Thromb Res; 2016 Jun; 142():44-51. PubMed ID: 27131284
[TBL] [Abstract][Full Text] [Related]
4. The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
Buijs JT; Laghmani EH; van den Akker RFP; Tieken C; Vletter EM; van der Molen KM; Crooijmans JJ; Kroone C; Le Dévédec SE; van der Pluijm G; Versteeg HH
J Thromb Haemost; 2019 Jun; 17(6):951-963. PubMed ID: 30929299
[TBL] [Abstract][Full Text] [Related]
5. Thrombin in complex with dabigatran can still interact with PAR-1 via exosite-I and instigate loss of vascular integrity.
Dólleman SC; Agten SM; Spronk HMH; Hackeng TM; Bos MHA; Versteeg HH; van Zonneveld AJ; de Boer HC
J Thromb Haemost; 2022 Apr; 20(4):996-1007. PubMed ID: 35037739
[TBL] [Abstract][Full Text] [Related]
6. Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease.
Sparkenbaugh EM; Chantrathammachart P; Mickelson J; van Ryn J; Hebbel RP; Monroe DM; Mackman N; Key NS; Pawlinski R
Blood; 2014 Mar; 123(11):1747-56. PubMed ID: 24449213
[TBL] [Abstract][Full Text] [Related]
7. Direct oral anticoagulants are associated with limited damage of endothelial cells of the blood-brain barrier mediated by the thrombin/PAR-1 pathway.
Puech C; Delavenne X; He Z; Forest V; Mismetti P; Perek N
Brain Res; 2019 Sep; 1719():57-63. PubMed ID: 31121158
[TBL] [Abstract][Full Text] [Related]
8. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Wong PC; Jiang X
Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa.
Ollivier V; Chabbat J; Herbert JM; Hakim J; de Prost D
Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1374-81. PubMed ID: 10807756
[TBL] [Abstract][Full Text] [Related]
10. TAK-442, a Direct Factor Xa Inhibitor, Inhibits Monocyte Chemoattractant Protein 1 Production in Endothelial Cells via Involvement of Protease-Activated Receptor 1.
Shinozawa E; Nakayama M; Imura Y
Front Pharmacol; 2018; 9():1431. PubMed ID: 30568593
[TBL] [Abstract][Full Text] [Related]
11. Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.
Spronk HM; de Jong AM; Crijns HJ; Schotten U; Van Gelder IC; Ten Cate H
Cardiovasc Res; 2014 Mar; 101(3):344-51. PubMed ID: 24385341
[TBL] [Abstract][Full Text] [Related]
12. Factor Xa induces tissue factor expression in endothelial cells by P44/42 MAPK and NF-κB-dependent pathways.
Jiang R; Wang NP; Tanaka KA; Levy JH; Guyton RA; Zhao ZQ; Vinten-Johansen J
J Surg Res; 2011 Aug; 169(2):319-27. PubMed ID: 20451919
[TBL] [Abstract][Full Text] [Related]
13. New oral anticoagulants: comparative pharmacology with vitamin K antagonists.
Scaglione F
Clin Pharmacokinet; 2013 Feb; 52(2):69-82. PubMed ID: 23292752
[TBL] [Abstract][Full Text] [Related]
14. Demeanor of rivaroxaban in activated/inactivated FXa.
Seki K; Mizuno Y; Sakashita T; Nakano S; Tanno J; Okazaki Y; Muramatsu T; Nishimura S; Senbonmatsu T
J Pharmacol Sci; 2017 Mar; 133(3):156-161. PubMed ID: 28314697
[TBL] [Abstract][Full Text] [Related]
15. Coagulation Factor Xa Induces Proinflammatory Responses in Cardiac Fibroblasts via Activation of Protease-Activated Receptor-1.
D'Alessandro E; Scaf B; Munts C; van Hunnik A; Trevelyan CJ; Verheule S; Spronk HMH; Turner NA; Ten Cate H; Schotten U; van Nieuwenhoven FA
Cells; 2021 Oct; 10(11):. PubMed ID: 34831181
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model.
Hosokawa K; Ohnishi T; Sameshima H; Miura N; Koide T; Maruyama I; Tanaka KA
PLoS One; 2014; 9(1):e86491. PubMed ID: 24497951
[TBL] [Abstract][Full Text] [Related]
17. Macrophage migration inhibitory factor is induced by thrombin and factor Xa in endothelial cells.
Shimizu T; Nishihira J; Watanabe H; Abe R; Honda A; Ishibashi T; Shimizu H
J Biol Chem; 2004 Apr; 279(14):13729-37. PubMed ID: 14736878
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Platelet-Rich Plasma on Endothelial Progenitor Cell Functionality.
Sidiropoulou S; Papadaki S; Tsouka AN; Koutsaliaris IK; Chantzichristos VG; Pantazi D; Paschopoulos ME; Hansson KM; Tselepis AD
Angiology; 2021 Sep; 72(8):776-786. PubMed ID: 33678047
[TBL] [Abstract][Full Text] [Related]
19. Blood coagulation factor Xa as an emerging drug target.
Borensztajn K; Spek CA
Expert Opin Ther Targets; 2011 Mar; 15(3):341-9. PubMed ID: 21250873
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].
Ordovás Baines JP; Climent Grana E; Jover Botella A; Valero García I
Farm Hosp; 2009; 33(3):125-33. PubMed ID: 19712596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
